A New Approach to Targeting Cancer Resistance
Disrupting
Calcium (ca)²⁺
Signaling
Tactical Therapeutics is advancing a novel therapeutic strategy focused on disrupting calcium (ca)²⁺ signaling—an essential process that drives tumor growth, survival, and resistance to treatment.
Our lead compound, CTO (Carboxyamidotriazole Orotate), is designed to target these pathways in a way that conventional therapies cannot.
Tactical Therapeutics
What Makes This Different
Beyond Single-Target Therapies
Most cancer treatments focus on a single pathway, allowing tumors to adapt and develop resistance. CTO takes a broader approach by targeting non-voltage-dependent calcium (ca)²⁺ signaling, a central regulator of multiple oncogenic processes.
This allows CTO to:
- Interfere with tumor cell proliferation
- Reduce angiogenesis (tumor blood vessel formation)
- Limit metastatic potential
- Disrupt survival signaling pathways including genomic, epigenetic, and immunologic including genomic, epigenetic and immunologic
Targeting Calcium (ca)²⁺ Signaling at the Core
Calcium (ca)²⁺ signaling plays a critical role in how cancer cells grow, survive, and spread. CTO inhibits this signaling, effectively disrupting the communication pathways tumors rely on.
By targeting this central mechanism, CTO impacts multiple downstream effects, making it harder for cancer cells to adapt or resist treatment.
Designed to
Reach the Brain
One of the greatest challenges in treating brain tumors is the blood-brain barrier, which prevents many therapies from reaching their target.
CTO is an oral therapy that has demonstrated the ability to cross the blood-brain barrier and achieve therapeutic concentrations within tumor tissue—making it especially promising for glioblastoma.
Why CTO Stands Apart
First-in-class & best-in-class calcium (ca)²⁺ signaling inhibitor
Oral, patient-friendly administration
Safe Toxicity Profile
Crosses The Blood-Brain-Barrier
Shows Efficiency in Phase Trials
A Platform for the Future of Oncology
Tactical Therapeutics is building a new foundation for cancer treatment—one that addresses the complexity of tumor biology and the limitations of existing therapies.
Our technology is designed not just to treat cancer, but to outmaneuver it.